Author

Chi‐Lu Chiu

Denali Therapeutics (United States)

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Neuroscience· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Research Focus:differential expression· 2 Approach:experimental assay· 2 Assay:proteomics· 2 Approach:statistical model· 2 Research Focus:benchmarking· 1 Research Focus:drug response / drug discovery· 1 Organism:mouse· 1

Frequent Co-Authors

Gilbert Di PaoloiD· 3 shared Jung H. SuhiD· 3 shared Sonnet S. DavisiD· 3 shared Anthony A. EstradaiD· 2 shared Bradley F. BoeveiD· 2 shared Casey A. Powers· 2 shared Fen HuangiD· 2 shared Hilary W. HeueriD· 2 shared

Activity by Year

2023-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersNeuroscience

Gilbert Di PaoloORCID

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Cerebrospinal fluid YWHAG:NPTX2 ratio predicts clinical severity and future phenoconversion in frontotemporal lobar degeneration

Hamilton Se‐Hwee Oh, Joshua D. Downer, Connor D. Dietz, Claire Yballa, Edoardo M. Marcora, Argentina Lario‐Lago, Hilary W. Heuer, Leah K. Forsberg, Jennifer Hsiao‐Nakamoto, Chi‐Lu Chiu, Paul Auger, Casey A. Powers, Gilbert Di Paolo, Fen Huang, Brian Stephen Appleby, , Scott J. Russo

The paper identifies the CSF YWHAG:NPTX2 ratio as a biomarker for predicting clinical severity and phenoconversion in FTLD, showing strong correlation with disease progression and improved trial design potential.

bioRxiv · Aug 31, 2026 · PreprintNeuroscience

LRRK2 Kinase Activity Regulates Parkinson's Disease-Relevant Lipids at the Lysosome

Michael T. Maloney, Xiang Wang, Rajarshi Ghosh, Shan V. Andrews, Romeo D. Maciuca, Shababa T. Masoud, Maayan R. Agam, Richard M. Caprioli, Giuseppe Astarita, Vitaliy V. Bondar, John Li Chen, Chi‐Lu Chiu, Sonnet S. Davis, Audrey Cheuk-Nga Ho, Hoang Ngan Nguyen, , Anastasia G. Henry

This study shows that LRRK2 kinase activity affects BMP and GSL levels in lysosomes, linking lysosomal dysfunction to Parkinson's disease through changes in GCase activity and BMP accumulation.

Molecular Neurodegeneration · Aug 6, 2025Peer-reviewedNeuroscience

Alterations in Lysosomal, Glial and Neurodegenerative Biomarkers in Patients with Sporadic and Genetic Forms of Frontotemporal Dementia

Jennifer Hsiao‐Nakamoto, Chi‐Lu Chiu, Lawren A. VandeVrede, Ritesh Ravi, Brittany Vandenberg, Jack De Groot, Buyankhishig Tsogtbaatar, Meng Fang, Paul Auger, Neal S. Gould, Filippo Marchioni, Casey A. Powers, Sonnet S. Davis, Jung H. Suh, Jamal I. Alkabsh, , Fen Huang

This study identifies and characterizes lysosomal, glial, and neurodegenerative biomarkers in cerebrospinal fluid and plasma from FTD patients, revealing their correlation with disease severity and tissue changes.

bioRxiv · Feb 9, 2024 · PreprintNeuroscience

DNL343 is an investigational CNS penetrant eIF2B activator that prevents and reverses the effects of neurodegeneration caused by the Integrated Stress Response

Ernie Yulyaningsih, Jung H. Suh, Melania H. Fanok, Roni Chau, Hilda O. Solanoy, Ryan Takahashi, Anna I. Bakardjiev, Isabel A. Becerra, N. Butch Benitez, Chi‐Lu Chiu, Sonnet S. Davis, William E. Dowdle, Timothy Earr, Anthony A. Estrada, Audrey Gill, , Pascal E. Sanchez

DNL343 reduces neurodegeneration in mouse models by inhibiting the integrated stress response and normalizing dysregulated biomarkers, with potential clinical relevance for vanishing white matter disease.

eLife · Nov 14, 2023Peer-reviewedNeuroscience